The estimated Net Worth of Harry W Jr Alcorn is at least 581 千$ dollars as of 15 September 2021. Dr Alcorn owns over 15,000 units of DiaMedica Therapeutics stock worth over 190,889$ and over the last 6 years he sold DMAC stock worth over 0$. In addition, he makes 389,925$ as Sr. VP of Clinical Operations at DiaMedica Therapeutics.
Dr has made over 5 trades of the DiaMedica Therapeutics stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 15,000 units of DMAC stock worth 57,000$ on 15 September 2021.
The largest trade he's ever made was buying 20,721 units of DiaMedica Therapeutics stock on 16 August 2021 worth over 64,028$. On average, Dr trades about 5,516 units every 126 days since 2018. As of 15 September 2021 he still owns at least 43,582 units of DiaMedica Therapeutics stock.
You can see the complete history of Dr Alcorn stock trades at the bottom of the page.
Dr. Harry W. Alcorn Jr., Pharm.D. is the Sr. VP of Clinical Operations at DiaMedica Therapeutics.
As the Sr. VP of Clinical Operations of DiaMedica Therapeutics, the total compensation of Dr D at DiaMedica Therapeutics is 389,925$. There are 2 executives at DiaMedica Therapeutics getting paid more, with Dietrich John Pauls MBA having the highest compensation of 687,579$.
Dr D is 65, he's been the Sr. VP of Clinical Operations of DiaMedica Therapeutics since . There are no older and 5 younger executives at DiaMedica Therapeutics.
Harry's mailing address filed with the SEC is TWO CARLSON PARKWAY, SUITE 260, MINNEAPOLIS, MN, 55447.
Over the last 6 years, insiders at DiaMedica Therapeutics have traded over 0$ worth of DiaMedica Therapeutics stock and bought 7,996,631 units worth 17,281,380$ . The most active insiders traders include Koch Thomas Tom Enterprise ...、Jantrill Ab Stahlberg、David J. Wambeke. On average, DiaMedica Therapeutics executives and independent directors trade stock every 48 days with the average trade being worth of 833,934$. The most recent stock trade was executed by Koch Thomas Tom Enterprise ... on 28 June 2024, trading 1,200,000 units of DMAC stock currently worth 3,000,000$.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
DiaMedica Therapeutics executives and other stock owners filed with the SEC include: